A prospective study found that RA patients who did not respond to methotrexate had lower pretreatment CD39 expression on Tregs than methotrexate-responsive patients or healthy controls, suggesting that low expression of CD39 on Tregs could be a biomarker for identifying methotrexate-resistant RA patients (34). This evidence concerns the gene ENTPD1 and rheumatoid arthritis.